We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Refutes Possible Link Between Heart Failure Therapy and Alzheimer’s
Novartis Refutes Possible Link Between Heart Failure Therapy and Alzheimer’s
A suggested link between Novartis’ heart failure drug LCZ696 and progression of Alzheimer’s disease could sour hopes of a pipeline replacement for the company’s failed Reasanz heart drug.